Corrections

The “Pipeline Plus” feature in the August issue of P&T incorrectly stated that the Food and Drug Administration approved lenvatinib (Lenvima, Eisai), in combination with everolimus, for second-line treatment of patients with advanced renal-cell carcinoma after prior antiangiogenic therapy in January 2016. The actual approval date was May 13, 2016.